Article
Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Sept 2020
Remon J, Tabbò F, Jimenez B, Collazo A, de Castro J, Novello S
Abstract excerpt
Next-generation ALK TKIs have become the new standard of care in first-line setting in advanced ALK-positive NSCLC patients. However, sequential strategies at progression are relevant, as may have an impact on patients' outcome. In this commentary we discuss whether genomic-tailored strategies at progression would be more suitable for improving outcome of ALK-positive NSCLC patients.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.